Malignant Genito-urinary Tumors in Children: South Egypt Cancer Institute Experience

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02557230

Enrollment

250

Registered

2015-09-23

Start date

2016-01-31

Completion date

2024-04-30

Last updated

2023-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genitourinary Neoplasms, Neoplasms, Genitourinary

Keywords

Childhood Cancer, Genitourinary tumors, urogenital tumors, Pediatric Oncology

Brief summary

The aim of this study is to identify demographic & disease characteristics in pediatric oncology patients diagnosed with one of genitourinary tumors & treatment outcomes in these patients.

Detailed description

Background: Tumors of the kidney, bladder, prostate, testis, and adrenal represent a large part of the adult urologic practice, but are relatively infrequent in children. Genitourinary tumors contribute to pediatric solid tumors. Wilms tumor, rhabdomyosarcoma, and germ cell tumors are the most common malignant genitourinary tumors in children. The natural history and management of these tumors in the pediatric age is different from that of the adults. As result of the successful work of several clinical trial groups in recent decades, there has been a significant improvement in their cure rates. Patients & Methods: From January 2001 till December 2015, retrieval & analysis of the medical records of pediatric patients with genitourinary tumors will be made at the pediatric oncology department, South Egypt Cancer Institute which represents the largest referral center in Upper Egypt. These data will be categorized according to demographic characteristics, clinico-pathologic features, treatment modalities received, and outcomes of treatments in these patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 18 Years

Healthy volunteers

Inclusion criteria

* Patients whose age less than or equal to 18 years. * Patients diagnosed with any of neoplasms affecting the genitourinary system.

Exclusion criteria

* Patients whose age more than 18 years.

Design outcomes

Primary

Measure	Time frame	Description
Overall survival (OS)	Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years	Time from the date of initiation of treatment until death from any cause
Event Free Survival (EFS)	Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years	Time from the date of initiation of treatment until disease progression, or death for any reason.

Countries

Egypt

Outcome results